文献速递生殖医学妇科

重新审视功能性下丘脑性无排卵患者的血清抗苗勒管激素水平

Revisiting the serum level of anti-Müllerian hormone in patients with functional hypothalamic anovulation.
PubMed 文献 · Hum Reprod · 2021-01-01

该回顾性观察研究比较45例功能性下丘脑性无排卵(FHA)患者与37例年龄和BMI匹配的对照,发现整体FHA患者血清AMH水平不降低;但排除多囊卵巢形态(PCOM)者后,FHA患者AMH显著低于对照(P<0.002)。

要点

  • FHA整体人群AMH水平与对照无显著差异。
  • 排除PCOM后,FHA患者AMH显著低于对照(P<0.002)。
  • 低LH伴AMH升高时不应误诊为PCOS。

核心结论

  • FHA整体人群血清AMH不降低,但排除PCOM后AMH显著降低。

研究设计与样本

  • 回顾性观察研究,纳入45例FHA患者与37例年龄和BMI匹配的对照。

主要发现

  • FHA与对照间AMH水平范围无显著差异。
  • 46.7%的FHA患者存在PCOM。
  • 排除PCOM后FHA患者AMH显著低于对照(P<0.002)。
  • FHA组内PCOM+者AMH和BMI秩次显著高于PCOM-者。
  • PCOM+亚组中LH、FSH和雄烯二酮仍低于对照(分别P<0.0001、<0.002、<0.05)。

关键数值与推荐

  • PCOM定义:每卵巢卵泡数≥12或≥19(取决于评估日期和超声设备),或AMH≥35 pmol/l替代卵泡数过多。

临床怎么用

  • 不应仅凭AMH降低诊断FHA患者卵巢储备低下。
  • 月经紊乱伴PCOM且AMH高但基础LH低时,不应误诊为PCOS。

局限性

  • 回顾性研究。
  • 对照来自ART中心,不代表一般人群。
  • PCOM采用修改分类和内部阈值。
  • 所用AMH检测方法已不再商用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Are serum levels of anti-Müllerian hormone (AMH) normal in patients with functional hypothalamic anovulation (FHA)? SUMMARY ANSWER: Our study confirms that in the general FHA population, serum AMH levels are not decreased, but if patients with polycystic ovarian morphology (PCOM) are excluded, levels become significantly lower, as in other situations of gonadotropic insufficiency. WHAT IS KNOWN ALREADY: In most situations of low LH (physiological, pharmacological or pathological), serum AMH levels are low. However, paradoxically, many publications have reported normal or even increased serum AMH levels in FHA patients. STUDY DESIGN, SIZE, DURATION: Retrospective observational study conducted in an academic centre. The data concerning the study population was collected between 2006 and 2015 from a database including clinical, biological and ultrasound information. PARTICIPANTS/MATERIALS, SETTING, METHODS: A total of 45 FHA patients were compared to 37 controls matched based on age and body mass index (BMI). Serum LH, FSH, androstenedione, total testosterone, prolactin and AMH levels were measured by immunoassay. We defined PCOM with strict criteria: a follicle number per ovary (FNPO) ≥ 12 or ≥ 19 per ovary, depending on the date on which the assessment was carried out and the ultrasound device. An AMH level ≥ 35 pmol/l could be a substitute for an excess FNPO. Controls meeting these criteria were not included in this study. MAIN RESULTS AND THE ROLE OF CHANCE: There was no significant difference in the ranges of AMH levels between FHA and controls. Using strict criteria to define PCOM status, 46.7% of FHA patients had PCOM. After excluding these patients, the levels of AMH were significantly lower (P < 0.002) in FHA patients compared to controls. Within the FHA group, patients with PCOM had significantly higher ranks of AMH levels and BMI than those without PCOM. However, within the PCOM+ subgroup, the ranks of LH, FSH and A levels were still lower than in controls (P < 0.0001, <0.002 and <0.05, respectively). The positive correlation between AMH and LH was significant in the controls but not in the FHA group. However, in the FHA PCOM+, there was a strong positive correlation between BMI and LH. LIMITATIONS, REASONS FOR CAUTION: This is a retrospective study; our controls did not represent the general population as they were recruited in an ART centre; we used a modified classification for PCOM using follicle count and/or AMH level with in-house thresholds to define the follicle excess; the AMH assay used is no longer commercially available. WIDER IMPLICATIONS OF THE FINDINGS: Besides biasing the results of AMH assay in FHA patients, the presence of PCOM in FHA patients despite low gonadotropin and androgen levels raises the issue of epigenetically acquired amplification of androgen and/or FSH sensitivity within granulosa cells from polycystic ovaries. In terms of clinical practice, it seems important not to diagnose a low ovarian reserve in FHA patients too quickly on the basis of a decreased AMH level alone. On the contrary, a high AMH level in the context of a menstrual disorder and PCOM should not lead to a misdiagnosis of polycystic ovary syndrome (PCOS) if the basal LH is low. STUDY FUNDING/COMPETING INTEREST(S): None. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Makolle S, Catteau-Jonard S, Robin G, et al. Revisiting the serum level of anti-Müllerian hormone in patients with functional hypothalamic anovulation. Hum Reprod. 2021. PMID: 33580689. doi:10.1093/humrep/deab024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。